Event-Free Survival
-
.ASH 2025: Ascentage Pharma Presents Four-Year Follow-Up Data from Phase II Registrational Study of Olverembatinib, Demonstrating Sustained Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
Ascentage Pharma (NASDAQ: AAPG) reported four‑year Phase II data for olverembatinib in TKI‑resistant/intolerant chronic‑phase CML. Median event‑free survival was 21.2 months versus 2.9 months for best available therapy (P = 0.0159). Responses favored olverembatinib (85% CHR, 38% CCyR, 30% MMR). Safety was acceptable, with 7% vascular‑occlusion events and some grade ≥3 hematologic toxicities. The drug is approved in China and covered by the national reimbursement list; global rights depend on a Takeda option, and three Phase III registrational studies are underway.
